ACHV | tickerfilter.com

Fundamental analysis

43%

Profitability 35%

Dept financing 39%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-34.57%

1 Month

-42.64%

3 Months

-40.32%

6 Months

-12.83%

1 Year

-4.68%

2 Year

-41.69%

Key data

Stock price

$2.65

P/E Ratio

N/A

DAY RANGE

$2.63 - $2.88

EPS

-$1.25

52 WEEK RANGE

$1.84 - $6.02

52 WEEK CHANGE

-$0.75

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

53.240 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.10

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,316,470

AVERAGE 30 VOLUME

$706,088

Company detail

CEO: John A. Bencich
Region: US
Website: achievelifesciences.com
Employees: 20
IPO year: 1995

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company is based in Vancouver, Canada and has license agreements with Sopharma AD and University of Bristol.

ACHV - ACHIEVE LIFE SCIENCES, INC.